Characteristics of patients treated with ibrutinib according to subtype
| Characteristic . | All patients (n = 54) . | Non-GCB (n = 24) . | GCB (n = 11) . | RT (n = 13) . | Unknown (n = 6) . | P . |
|---|---|---|---|---|---|---|
| Age at diagnosis, y, median (range) | 62 (38-88) | 61 (38-88) | 61 (47-79) | 61 (47-80) | 68 (40-71) | .97 |
| Sex, no. (%) | ||||||
| Men | 33 (61) | 15 (63) | 4 (36) | 9 (69) | 5 (83) | .27 |
| Women | 21 (39) | 9 (37) | 7 (64) | 4 (31) | 1 (17) | |
| IPI at diagnosis, no. (%) | ||||||
| Low | 14 (26) | 5 (21) | 4 (36) | 4 (31) | 1 (17) | .78 |
| Low intermediate | 11 (20) | 7 (29) | 1 (9) | 2 (15) | 1 (17) | |
| High intermediate | 13 (24) | 7 (29) | 1 (9) | 3 (23) | 2 (33) | |
| High | 16 (30) | 5 (21) | 5 (46) | 4 (31) | 2 (33) | |
| Number of prior treatments | ||||||
| Median | 3 | 3 | 3 | 3.0 | 4 | .61 |
| Range | 1-11 | 1-8 | 2-8 | 1-11 | 2-5 | |
| Prior transplant,* no. (%) | 17 (31) | 6 (25) | 5 (46) | 3 (23) | 3 (50) | .42 |
| CNS disease at diagnosis, no. (%) | 6 (11) | 4 (17) | 0 (0) | 1 (8) | 1 (17) | .53 |
| Characteristic . | All patients (n = 54) . | Non-GCB (n = 24) . | GCB (n = 11) . | RT (n = 13) . | Unknown (n = 6) . | P . |
|---|---|---|---|---|---|---|
| Age at diagnosis, y, median (range) | 62 (38-88) | 61 (38-88) | 61 (47-79) | 61 (47-80) | 68 (40-71) | .97 |
| Sex, no. (%) | ||||||
| Men | 33 (61) | 15 (63) | 4 (36) | 9 (69) | 5 (83) | .27 |
| Women | 21 (39) | 9 (37) | 7 (64) | 4 (31) | 1 (17) | |
| IPI at diagnosis, no. (%) | ||||||
| Low | 14 (26) | 5 (21) | 4 (36) | 4 (31) | 1 (17) | .78 |
| Low intermediate | 11 (20) | 7 (29) | 1 (9) | 2 (15) | 1 (17) | |
| High intermediate | 13 (24) | 7 (29) | 1 (9) | 3 (23) | 2 (33) | |
| High | 16 (30) | 5 (21) | 5 (46) | 4 (31) | 2 (33) | |
| Number of prior treatments | ||||||
| Median | 3 | 3 | 3 | 3.0 | 4 | .61 |
| Range | 1-11 | 1-8 | 2-8 | 1-11 | 2-5 | |
| Prior transplant,* no. (%) | 17 (31) | 6 (25) | 5 (46) | 3 (23) | 3 (50) | .42 |
| CNS disease at diagnosis, no. (%) | 6 (11) | 4 (17) | 0 (0) | 1 (8) | 1 (17) | .53 |
CNS, central nervous system; IPI, International Prognostic Index.
All transplants were autologous except 2, who received allogeneic transplants (1 with GCB subtype and 1 with non-GCB subtype).